Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

London, March 21, 2023 – Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases , today announced regulatory feedback following recent end-of-Phase 2 meetings with t he U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) related to its alvelestat program for the treatment of alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD). Company to host conference call today at 8:30am ET. Mereo BioPharma will hold a conference call today, March 21, at 8:30am ET. To participate by telephone, please dial (877) 418-5268 in the U.S., or ( 412) 902-6771 internationally, and ask for the Mereo BioPharma Group Conference Call. Alternatively you can access via http://www.wsw.com/webcast/cc/ mph.l4 Privacy Notice Cookie Notice Medical Inquiries LinkedIn NASDAQ: MREO Share Price: Mereo BioPharma Group plc ©2026 Last Updated: July 2025 Welcome This page is intended for Healthcare Professionals only. Please confirm that you are a Healthcare Professional. Yes No You are now leaving the Mereo BioPharma website. This link is provided as a courtesy. Mereo BioPharma is not responsible for the content or privacy practices of external websites. We recommend reviewing the privacy policy of any site you choose to visit. Click 'Cancel' to stay on the Mereo BioPharma website, or 'Continue' to proceed to the external site. Continue Cancel

The release as fetched from its publisher. mereobiopharma.com ↗